La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Unity Biotechnology a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Unity Biotechnology..

Unity Biotechnology (NASDAQ:UBX) Azioni, Catena delle Opzioni

Unity Biotechnology

Unity Biotechnology Inc designs therapeutics that prevent, halt, and reverse various diseases of aging. The company focuses on clearing senescent cells, and creating senolytic medicines. Its medicines target vulnerabilities unique to senescent cells to clear those cells from the human body while leaving normal cells unaffected. The firm focuses on age-associated diseases such as osteoarthritis, eye diseases, and pulmonary diseases. Its drug candidates include, UBX1325 is being developed for age-related diseases of the eye, including diabetic macular edema, or DME, UBX2089, which is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, which is being researched for multiple neurology indications, and UBX2050.

Unity Biotechnology Inc

UBIX.Network

U-BX Technology Ltd

UpBots

Morgan Stanley analyst Michael Cyprys maintains StepStone Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STEP#NASDAQ">STEP</a>) with a Equal-Weight and raises the price target from $60 to $65.

News

Price Target

Analyst Ratings

STEP

Morgan Stanley Maintains Equal-Weight on StepStone Group, Raises Price Target to $65

Morgan Stanley analyst Brian Morton maintains Smurfit WestRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SW#NYSE">SW</a>) with a Overweight and raises the price target from $60 to $64.

Morgan Stanley Maintains Overweight on Smurfit WestRock, Raises Price Target to $64

WIIM

QMCO

Quantum shares are trading lower after the company reported worse-than-expected Q2 financial results and issued Q3 sales guidance below estimates.

BRAG

Bragg Gaming Group shares are trading lower. The company reported Q3 financial results.

Morgan Stanley analyst Tejas Savant maintains Natera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>) with a Overweight and raises the price target from $132 to $176.

NTRA

Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $176

Morgan Stanley analyst Meta Marshall maintains Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) with a Equal-Weight and raises the price target from $61 to $76.

LITE

Morgan Stanley Maintains Equal-Weight on Lumentum Holdings, Raises Price Target to $76

Morgan Stanley analyst Adam Jonas maintains Lear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEA#NYSE">LEA</a>) with a Overweight and lowers the price target from $145 to $135.

Morgan Stanley Maintains Overweight on Lear, Lowers Price Target to $135

Jefferies analyst Michael Sarcone initiates coverage on PROCEPT BioRobotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRCT#NASDAQ">PRCT</a>) with a Hold rating and announces Price Target of $95.

Initiation

PRCT

Jefferies Initiates Coverage On PROCEPT BioRobotics with Hold Rating, Announces Price Target of $95

VISL

Vislink Technologies shares are trading lower after the company reported worse-than-expected Q3 financial results.

Cadence Design Sys's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDNS#NYSE">CDNS</a>) short percent of float has risen 19.26% since its last report. The company recently reported that it has 3.92 million shares sold short, which is 1.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.36 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cadence Design Sys Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731601821_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cadence Design Sys has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Cadence Design Sys's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cadence Design Sys's peer group average for short interest as a percentage of float is 3.40%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

CDNS

Looking Into Cadence Design Sys's Recent Short Interest

Graphic Packaging Holding's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPK#NYSE">GPK</a>) short percent of float has risen 3.17% since its last report. The company recently reported that it has 17.55 million shares sold short, which is 7.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.43 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Graphic Packaging Holding Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731601816_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Graphic Packaging Holding has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Graphic Packaging Holding's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Graphic Packaging Holding's peer group average for short interest as a percentage of float is 4.42%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Graphic Packaging Holding's Recent Short Interest

PXDT

Pixie Dust Technologies Shares Resume Trade Then Again Halt On Circuit Breaker To The Upside, Stock Now Up 180%

RTX's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) short percent of float has fallen 3.12% since its last report. The company recently reported that it has 12.39 million shares sold short, which is 0.93% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.79 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>RTX Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731601811_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for RTX has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing RTX's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, RTX's peer group average for short interest as a percentage of float is 3.11%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(RTX) - Analyzing RTX's Short Interest

MTEM

Molecular Templates Shares Resume Trade

TRNR

Interactive Strength shares are trading lower. The company reported Q3 financial results.

Morgan Stanley analyst Devin McDermott maintains Coterra Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) with a Equal-Weight and raises the price target from $27 to $29.

CTRA

Morgan Stanley Maintains Equal-Weight on Coterra Energy, Raises Price Target to $29

Earnings

Interactive Strength Q3 EPS $(1.53) Up From $(29.35) YoY, Sales $2.00M

AgEagle Aerial Systems Inc (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/UAVS#AMEX">UAVS</a>) shares are soaring Thursday after the company announced new purchase orders from <a href="https://www.benzinga.com/pressreleases/24/11/g41969974/ageagle-aerial-systems-secures-17-new-purchase-orders-for-ebee-tac-drones-from-u-s-defense-and-sec">U.S. defense and security customers</a>.
What Happened: AgEagle said it secured 17 new purchase orders for eBee TAC drones from U.S. defense and security customers. The company&#8217;s eBEE TAC drones provide tactical mapping capabilities.
&#8220;We are grateful to reach a pivotal milestone in the execution of our U.S. defense and security market growth strategy outlined previously in my letter to shareholders,&#8221; said Bill Irby, CEO of AgEagle.
&#8220;With the increasing demand for our eBee TAC drones, we are strategically positioned to lead in the Tactical Intelligence, Surveillance, and Reconnaissance (ISR) vertical. This demand fuels our commitment to developing innovative UAS platforms designed to solve complex operational challenges and close critical gaps in tactical ISR.&#8221;
Irby wrote a letter to shareholders last month outlining the company&#8217;s new mission of &#8220;reaching beyond to provide unmatched insights that enhance operations, safeguard communities and optimize productivity.&#8221;
The company narrowed its vertical markets from 11 to three, reshaped its portfolio of drones and initiated a size optimization project to &#8220;meet increasing demand.&#8221;
Irby noted that the company had already booked the purchase orders for the 17 eBee TAC drones in his letter last month. 
&#8220;In conclusion, through a combination of our key initiatives, growing demand, and demonstrated progress in our newest market, I believe AgEagle is on the correct path to increase long-term shareholder value,&#8221; the AgEagle CEO said.
UAVS Price Action: <a href="http://benzinga.com/quote/uavs">AgEagle shares</a> were up 115% at $3.46 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/41973572/ray-dalios-bridgewater-cuts-stake-in-microsoft-stock-by-20-is-big-tech-losing-its-shine">Ray Dalio&#8217;s Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?</a></li>
</ul>
Photo: Pixabay.

Contracts

Movers

UAVS

What's Going On With AgEagle Aerial Systems Stock Today?

Morgan Stanley analyst Brian Harbour maintains Cava Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAVA#NYSE">CAVA</a>) with a Equal-Weight and raises the price target from $123 to $135.

CAVA

Morgan Stanley Maintains Equal-Weight on Cava Group, Raises Price Target to $135

Jefferies analyst Brent Thill maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Buy and raises the price target from $280 to $300.

TEAM

Jefferies Maintains Buy on Atlassian, Raises Price Target to $300

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Unity Biotechnology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ubx-stock-quote/">UBX</a>) just reported results for the fourth quarter of 2023.<ul><li>Unity Biotechnology reported earnings per share of -28 cents. This was above the analyst estimate for EPS of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/04/ubx-stock-earnings-unity-biotechnology-for-q4-of-2023/">UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

UBX Stock Earnings: Unity Biotechnology Beats EPS for Q4 2023

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bioxcel Therapeutics (BTAI – Research Report) and Unity Biotechno...

Analysts Offer Insights on Healthcare Companies: Bioxcel Therapeutics (BTAI) and Unity Biotechnology (UBX)

Unity Biotechnology GAAP EPS of -$0.34

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Unity Biotechnology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ubx-stock-quote/">UBX</a>) just reported results for the first quarter of 2024.<ul><li>Unity Biotechnology reported earnings per share of -34 cents. This was above the analyst estimate for EPS of -48 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/ubx-stock-earnings-unity-biotechnology-for-q1-of-2024/">UBX Stock Earnings: Unity Biotechnology Beats EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

UBX Stock Earnings: Unity Biotechnology Beats EPS for Q1 2024

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Unity Biotechnology (UBX – Research Report). The associated price t...

Buy Rating on Unity Biotechnology: Promising Future for UBX1325 in Diabetic Macular Edema Treatment

Unity Biotechnology GAAP EPS of -$0.31 beats by $0.15

Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Unity Biotechnology (UBX – Research Report) and keeping the price target a...

Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Foselutoclax Trial Results and Strong Financial Position

Unity Biotechnology GAAP EPS of -$0.38 beats by $0.02

Unity Biotech ( ($UBX) ) has released its Q3 earnings. Here is a breakdown of the information Unity Biotech presented to its investors. Unity Biote...

Unity Biotechnology Focuses on Promising DME Treatment

Unity Biotech (UBX) has disclosed a new risk, in the Regulation category. Unity Biotech faces significant risks due to potential noncompliance with...

Comments

Unity Biotechnology

Unity Biotechnology (UBX) Opzioni

Unity Biotechnology (NASDAQ:UBX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO